Released : February 04, 2021 07:00 RNS Number : 9342N MaxCyte, Inc. 04 February 2021 GENERAL TEXT AMENDMENT The following amendment(s) have been made to the ' MaxCyte Announces £40 million Subscription' announcement released on 03/02/2021 at 16.36 under RNS No 9191N. References to "T.
Released : February 03, 2021 16:36 RNS Number : 9191N MaxCyte, Inc. 03 February 2021 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY
Released : February 03, 2021 16:35 RNS Number : 9190N MaxCyte, Inc. 03 February 2021 MaxCyte, Inc. (" MaxCyte " or the " Company ") Appointment of Joint Corporate Broker Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company
Released : January 21, 2021 14:49 RNS Number : 5100M MaxCyte, Inc. 21 January 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Increase to Block Listing, Block Listing Return and Total Voting Rights MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life
Released : January 20, 2021 07:00 RNS Number : 2360M MaxCyte, Inc. 20 January 2021 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Full-year revenues at $26.2m (21% growth over FY 2019) and second half revenue at $15.3m (15% over
Myeloid to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma CAMBRIDGE, MA and GAITHERSBURG, MD, January 11, 2021 — Myeloid Therapeutics, Inc., a company harnessing and reprogramming
Released : January 11, 2021 07:00 RNS Number : 1564L MaxCyte, Inc. 11 January 2021 Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs Myeloid to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™